Pneumocystis Pneumonia Clinical Trial
Official title:
A Case-control Study on Risk Factors, Timing, and PCR Use, for Pneumocystis Pneumonia (PcP) After Allogeneic HSCT
The fungus Pneumocystis jirovecii is responsible for pneumocystosis (PcP), a life threatening pneumonia in patients undergoing HSCT. The spontaneous attack rate of 16% within the first 6 months following allogeneic HSCT reported in the 1980's has considerably decreased with prophylaxis. However, PcP still remains a concern in the transplant ward with an incidence rate up to 2.5% in allo- and 1.4% in autologous HSCT but up to 7.2% on low dose of Dapsone. The mortality of PcP is especially high in HSCT recipients. One of the main factors of PcP after HSCT seems to be either the lack of TMP-SMX prophylaxis (all the other prophylactic drugs being inferior to TMP-SMX), or poor compliance to prophylaxis. Due to the rarity of the disease after HSCT, it is impossible to study it in monocenter studies, except on very long periods of time which may not reflect current practice. Several questions deserve investigations in a multicenter study, about timing, risk factors, and outcome. Moreover, some European laboratories involved in the diagnosis of PcP have already given up to classical diagnostic methods and switched to qPCR. This implies that lower fungal burden can be detected and the clinical pertinence of such a diagnostic strategy deserves to be assessed.
Due to the lack of standardization, qPCR on sputum only will not be taken in account for the diagnosis of PcP. Knowing this is a non-interventional study, no additional visits or laboratory tests will be performed for the study. Only the available data will be collected. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02603575 -
Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients
|
N/A | |
| Recruiting |
NCT05835479 -
Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
|
Phase 2 | |
| Recruiting |
NCT05605145 -
PCP in Immunocompromised Population in Southern China
|
||
| Completed |
NCT03087890 -
Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria
|
Phase 4 | |
| Not yet recruiting |
NCT04851015 -
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
|
Phase 3 | |
| Not yet recruiting |
NCT06431958 -
Droplet Digital PCR and PCR-free BIOSensors for the Detection of Resistance-associated SNPs in Pneumocystis Jirovecii
|
||
| Not yet recruiting |
NCT06442345 -
Pneumocystis Jirovecii Genotyping
|
||
| Recruiting |
NCT02550080 -
Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome
|
Phase 4 | |
| Completed |
NCT00869544 -
Pneumocystis in Pathogenesis of HIV-associated Emphysema
|
||
| Recruiting |
NCT03978559 -
Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP
|
Phase 4 | |
| Completed |
NCT04358419 -
Non-invasive Diagnosis of Invasive Pulmonary Aspergillosis by Use of Biomarkers in Exhaled Breath Condensate
|